86 related articles for article (PubMed ID: 9626219)
1. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
3. Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1998; 41(5):423-6. PubMed ID: 9523740
[TBL] [Abstract][Full Text] [Related]
4. KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Clarke K; Basser RL; Underhill C; Mitchell P; Bartlett J; Cher L; Findlay M; Dalley D; Pell M; Byrne M; Geldard H; Hill JS; Maher D; Fox RM; Green MD; Kaye AH
J Clin Oncol; 1999 Aug; 17(8):2579-84. PubMed ID: 10561325
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Kuratsu JI; Arita N; Kayama T; Kubo N; Mori T; Sawamura Y; Ushio Y
J Neurooncol; 2000 Jun; 48(2):145-9. PubMed ID: 11083079
[TBL] [Abstract][Full Text] [Related]
6. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Tabata M; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Fukutani H; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2361-6. PubMed ID: 2546503
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL
J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
10. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
11. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Kubota T; Suto A; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Jpn J Cancer Res; 1990 Aug; 81(8):827-33. PubMed ID: 2144515
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Kuratsu J; Arita N; Kurisu K; Uozumi T; Hayakawa T; Ushio Y
J Neurooncol; 1999 Apr; 42(2):177-81. PubMed ID: 10421076
[TBL] [Abstract][Full Text] [Related]
15. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
